

Application for Free Membership

This application for membership must be signed and dated by the applicant, and signed by a proposer and seconder on your behalf (whom are both current members of the AGITG). If two registered members are not available, please leave second nominator blank, and applicants may be seconded by members of the Board of Directors.

Applications will be considered at the next meeting of the Board of Directors and applicants will be notified by mail of membership approval.

Please indicate below if you require a copy of the Constitution of the Group.

I hereby apply for membership of the AGITG, and in doing so agree to uphold the principles of the Group and promote its objectives.

Applicant Details

TITLE	FULL NAME	APPLICANT SPECIALTY
BUSINESS ADDRESS		
PHONE	FAX	MOBILE
EMAIL		
DATE	SIGNATURE	

Nominators

Proposer (Registered Member)			
TITLE	FULL NAME	SIGNATURE	DATE

Seconder (Registered Member)			
TITLE	FULL NAME	SIGNATURE	DATE

Please tick if you require a copy of the Constitution of the Group

RETURN FORM TO: AGITG Co-ordinating Centre
Locked Bag 77,
Camperdown NSW 1450

ph: (02) 9562 5340
fax: (02) 9562 5348
website: www.gicancer.org.au
email: AGITG@ctc.usyd.edu.au

OFFICE
USE
ONLY

Membership Accepted? Yes No

DATE ACCEPTED

Acceptance letter sent

Over 700 health professionals volunteering their expertise in clinical trials

The Australasian Gastro-Intestinal Trials Group (AGITG) is a not-for-profit organisation that facilitates and co-ordinates clinical trial research in GI cancer (cancer of the oesophagus, stomach, liver, gallbladder, pancreas and bowel) across Australasia and in the UK. Collaborating with institutions in Asia, Europe and the USA, AGITG is fast becoming an internationally pre-eminent research organisation, recognised by its peers for exceptional conduct and reporting of important clinical research.

Since its inception in 1991, AGITG has been instrumental in establishing networks of investigators capable of conducting multidisciplinary clinical research. In addition, the AGITG has established the necessary structures and processes to support the development and implementation of novel clinical research concepts. The aim is to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer.

The Group is made up of over 700 members – including surgeons, medical and radiation oncologists, gastroenterologists, nuclear medicine physicians, palliative care specialists, data managers, research nurses, pharmacists, statisticians, pathologists and other health professionals. These dedicated members are based at 69 hospital and research centres across the globe.

The AGITG was initially established as an unincorporated association in 1991, and formed as a Company Limited by Guarantee in July 2000. The NHMRC Clinical Trials Centre at the University of Sydney is the co-ordinating centre for the group and is responsible for the co-ordination of AGITG clinical trials. The AGITG is committed to excellence, innovation and leadership in meeting the health care needs of the people it serves, improving community health, and fostering the very best medical research.

AGITG mission statement

To continually achieve better health outcomes for patients with gastro-intestinal cancers by conducting and promoting clinical research, addressing key clinical questions.

AGITG scientific objects

- To encourage members of the medical and scientific community through participation to assist in the conduct, evaluation, promotion and development of clinical trials in gastro-intestinal cancer.
- To promote the use of clinical trials in evaluating new treatments in gastro-intestinal malignancy and to improve the impact of new clinical trials on future clinical practice.
- To promote and conduct medical research for the prevention and mitigation of gastro-intestinal cancer,
- To promote improved clinical practice through professional meetings and educational symposia by working in collaboration with professional societies to pursue the objectives of (a), (b) and (c).
- To promote public education and awareness of gastro-intestinal cancer and its treatment, and
- To freely publish the results of research and clinical trials and to make available for general use, on the same terms to all interested bodies, licences for Australia and New Zealand patents issued in the course of research and clinical trials.

